Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection

J. R. Wands, M. Geissler, J. Z U Putlitz, H. Blum, F. Von Weizsäcker, L. Mohr, S. K. Yoon, M. Melegari, P. P. Scaglioni

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to vital structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.

Original languageEnglish (US)
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume12
Issue number9-10
StatePublished - 1997

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Genetic Therapy
Nucleic Acids
Antiviral Agents
Infection
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Virus Diseases
Cellular Immunity
Antisense DNA
Viral Core Proteins
Dominant Genes
Antisense RNA
Nucleocapsid
DNA
Antigen Presentation
Mutant Proteins
Chronic Hepatitis
Humoral Immunity

Keywords

  • Antisense RNA and DNA
  • Gene therapy
  • Vital hepatitis B

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Wands, J. R., Geissler, M., Putlitz, J. Z. U., Blum, H., Von Weizsäcker, F., Mohr, L., ... Scaglioni, P. P. (1997). Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. Journal of Gastroenterology and Hepatology (Australia), 12(9-10).

Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. / Wands, J. R.; Geissler, M.; Putlitz, J. Z U; Blum, H.; Von Weizsäcker, F.; Mohr, L.; Yoon, S. K.; Melegari, M.; Scaglioni, P. P.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 12, No. 9-10, 1997.

Research output: Contribution to journalArticle

Wands, JR, Geissler, M, Putlitz, JZU, Blum, H, Von Weizsäcker, F, Mohr, L, Yoon, SK, Melegari, M & Scaglioni, PP 1997, 'Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection', Journal of Gastroenterology and Hepatology (Australia), vol. 12, no. 9-10.
Wands JR, Geissler M, Putlitz JZU, Blum H, Von Weizsäcker F, Mohr L et al. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. Journal of Gastroenterology and Hepatology (Australia). 1997;12(9-10).
Wands, J. R. ; Geissler, M. ; Putlitz, J. Z U ; Blum, H. ; Von Weizsäcker, F. ; Mohr, L. ; Yoon, S. K. ; Melegari, M. ; Scaglioni, P. P. / Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. In: Journal of Gastroenterology and Hepatology (Australia). 1997 ; Vol. 12, No. 9-10.
@article{5d99c5334f484c92a7fdbfd22f457b5c,
title = "Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection",
abstract = "Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to vital structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.",
keywords = "Antisense RNA and DNA, Gene therapy, Vital hepatitis B",
author = "Wands, {J. R.} and M. Geissler and Putlitz, {J. Z U} and H. Blum and {Von Weizs{\"a}cker}, F. and L. Mohr and Yoon, {S. K.} and M. Melegari and Scaglioni, {P. P.}",
year = "1997",
language = "English (US)",
volume = "12",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9-10",

}

TY - JOUR

T1 - Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection

AU - Wands, J. R.

AU - Geissler, M.

AU - Putlitz, J. Z U

AU - Blum, H.

AU - Von Weizsäcker, F.

AU - Mohr, L.

AU - Yoon, S. K.

AU - Melegari, M.

AU - Scaglioni, P. P.

PY - 1997

Y1 - 1997

N2 - Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to vital structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.

AB - Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to vital structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.

KW - Antisense RNA and DNA

KW - Gene therapy

KW - Vital hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=0030830417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030830417&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9-10

ER -